Ipsen Completes Acquisition of Memo Therapeutics to Advance BK Polyomavirus Treatment

Deal brings potravitug into Ipsen's portfolio as company targets unmet need in kidney transplant care

Ipsen has completed its acquisition of Memo Therapeutics AG, a late-stage biotechnology company developing potravitug, an investigational monoclonal antibody designed to target BK polyomavirus in kidney transplant recipients.

The acquisition gives Ipsen control of potravitug, which is being developed as a potential first-in-class treatment for BK polyomavirus reactivation.

The deal also adds a late-stage program to Ipsen's pipeline as the company expands its focus on serious diseases where patients have limited treatment options.

Potravitug Targets BK Polyomavirus Reactivation

Potravitug is a monoclonal antibody designed to target BK polyomavirus, commonly called BKPyV.

The virus is very common. Most people are exposed to it during childhood, and it usually stays inactive in the body without causing major problems.

The situation can change when a person's immune system is weakened.

This is particularly important for kidney transplant recipients. These patients take medicines that suppress the immune system to prevent their bodies from rejecting the transplanted kidney.

When the immune system is suppressed, BKPyV can become active again and start multiplying.

In some patients, this can lead to BK polyomavirus-associated nephropathy, or BKVAN, which can damage the transplanted kidney.

BKPyV Is a Major Concern After Kidney Transplantation

Around 90% of kidney transplant recipients are positive for the BKPyV serotype.

During the first year after transplantation, high levels of BKPyV in the blood are seen in around 30% of patients, indicating that the virus has reactivated.

For some patients, the infection can become a serious problem.

BKPyV reactivation and BKVAN can increase the risk of losing the transplanted kidney. Patients may eventually require dialysis or another transplant.

At present, there are no approved targeted therapies specifically designed to treat BKPyV.

Doctors generally manage the problem by reducing immunosuppressive medicines. The challenge is that these medicines are also needed to protect the transplanted kidney from rejection.

This creates a difficult balance between controlling the virus and protecting the transplant.

Phase II Data Support Potravitug Development

The development of potravitug is supported by data from the Phase II SAFE KIDNEY II trial.

The study is described as the largest placebo-controlled trial conducted in kidney transplant recipients with BKPyV.

Clinical trial results showed a significant antiviral response with potravitug, along with resolution of BKPyV-associated nephropathy in treated patients.

Additional analyses from the program have also been presented at major international kidney and transplant medical congresses.

Ipsen believes these findings support the continued development of potravitug and provide a basis for planning the next stages of clinical development.

Why BKPyV Treatment Matters for Kidney Transplant Patients

A successful kidney transplant can give patients a chance to move away from long-term dialysis and improve their quality of life.

However, complications such as BKPyV reactivation can threaten the transplanted organ.

More than 100,000 kidney transplants are performed worldwide every year.

In the US alone, more than 28,000 kidney transplants are carried out each year, while more than 90,000 people remain on the waiting list for a transplant.

With so many patients relying on transplanted kidneys, there is a clear need for better ways to manage infections that can put the transplant at risk.

Ipsen Adds a New Late-Stage Program

The acquisition of Memo Therapeutics gives Ipsen access to potravitug at a late stage of development.

The company plans to continue advancing the program and evaluating its potential role in protecting kidney transplant recipients affected by BKPyV reactivation.

The program also fits into Ipsen's broader strategy of bringing innovative medicines to patients with serious diseases and areas where current treatment options remain limited.

A Potential New Approach to BKPyV Management

The current approach to BKPyV management largely depends on adjusting immunosuppressive treatment.

While this can help control the virus, reducing immunosuppression can also increase the risk of transplant rejection.

A targeted antibody such as potravitug could offer a different approach by directly addressing the virus.

The potential benefit is that doctors may have another tool to manage BKPyV without relying only on reductions in immunosuppressive treatment.

Further clinical development will be needed to determine the full potential of potravitug and its role in the treatment of BKPyV reactivation and associated nephropathy.

Ipsen Expands Its Biopharmaceutical Pipeline

Ipsen is a global biopharmaceutical company focused on developing medicines in oncology, rare diseases and neuroscience.

The company combines internal research with external innovation and partnerships to expand its pipeline.

With nearly 100 years of experience in drug development, Ipsen operates through global hubs in the United States, France and the United Kingdom.

The acquisition of Memo Therapeutics adds a late-stage kidney transplant-focused program to its portfolio and gives Ipsen an opportunity to advance potravitug for a patient population that currently has no approved targeted therapy for BK polyomavirus.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!